Stock RCUS ARCUS BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Real-time Estimate Cboe BZX
Other stock markets
 01:28:45 2024-05-02 pm EDT 		5-day change 1st Jan Change
15.62 USD +0.81% Intraday chart for Arcus Biosciences, Inc. +6.25% -18.06%
Mar. 12 Transcript : Arcus Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM
Feb. 29 Arcus Biosciences Insider Sold Shares Worth $1,177,967, According to a Recent SEC Filing MT

Evolution of the average Target Price on Arcus Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

40.QYyb2b3myUdSRfl_9oKyyNNaWmiexrOICpPW9ZsKNhw.N__essW3jg00Mqs9mrbqgJo2bSTXqIPJPeu1hu5Pbisl3O6A6LSEIwRyyQ~5635ca61d07fbf40b24c5991cf70dcef

Analyst Recommendations on Arcus Biosciences, Inc.

Mizuho Adjusts Arcus Biosciences' Price Target to $42 From $51, Keeps Buy Rating MT
Wedbush Lowers Arcus Biosciences' PT to $30 From $36 After Announced Plans to Discontinue Enrollment for Phase 3 ARC-10 Study; Keeps Outperform Rating MT
Morgan Stanley Cuts Price Target on Arcus Biosciences to $35 From $38, Maintains Overweight Rating MT
Cantor Fitzgerald Adjusts Arcus Biosciences' Price Target to $36 From $46, Maintains Overweight Rating MT
Citigroup Adjusts Price Target on Arcus Biosciences to $44 From $41, Maintains Buy Rating MT
Morgan Stanley Trims Price Target on Arcus Biosciences to $38 From $40, Maintains Overweight Rating MT
Cantor Fitzgerald Reiterates Arcus Biosciences' Overweight Rating, $46 Price Target MT
Citigroup Adjusts Arcus Biosciences Price Target to $41 From $40, Maintains Buy Rating MT
Barclays Adjusts Price Target on Arcus Biosciences to $35 From $60, Maintains Overweight Rating MT
Citigroup Adjusts Arcus Biosciences' Price Target to $42 From $37, Keeps Buy Rating MT
Citigroup Lowers Price Target on Arcus Biosciences to $37 From $40, Maintains Buy Rating MT
BofA Securities Starts Arcus Biosciences at Neutral With $33 Price Target MT
SVB Securities Adjusts Price Target on Arcus Biosciences to $38 From $40, Maintains Outperform Rating MT
Berenberg Bank Adjusts Arcus Biosciences Price Target to $60 From $68, Maintains Buy Rating MT
Morgan Stanley Starts Arcus Biosciences at Overweight With $40 Price Target MT
Goldman Sachs Adjusts Arcus Biosciences' Price Target to $29 From $28, Maintains Neutral Rating MT
SVB Securities Adjusts Arcus Biosciences' Price Target to $49 from $66, Keeps Outperform Rating MT
Wedbush Adjusts Price Target on Arcus Biosciences to $36 From $42, Keeps Outperform Rating MT
Truist Securities Adjusts Arcus Biosciences' Price Target to $50 from $77, Keeps Buy Rating MT
Goldman Sachs Adjusts Arcus Biosciences Price Target to $28 From $48, Maintains Neutral Rating MT
Wedbush Lowers Arcus Biosciences' Price Target to $42 from $67, Notes Increased Risk for TIGIT Program; Keeps Outperform Rating MT
Goldman Sachs Adjusts Arcus Biosciences' Price Target to $43 From $45; Neutral Rating Kept MT
Berenberg Bank Adjusts Arcus Biosciences' Price Target to $68 From $60, Maintains Buy Rating MT
Citigroup Adjusts Price Target on Arcus Biosciences to $53 From $42, Reiterates Buy Rating MT
Barclays Adjusts Price Target on Arcus Biosciences to $60 From $48, Keeps Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
15.5 USD
Average target price
38.89 USD
Spread / Average Target
+150.90%
High Price Target
70 USD
Spread / Highest target
+351.61%
Low Price Target
24 USD
Spread / Lowest Target
+54.84%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Arcus Biosciences, Inc.

Mizuho Securities
Wedbush
Morgan Stanley
Cantor Fitzgerald
Citigroup
Barclays
BofA Securities
Berenberg Bank
SVB Securities LLC
Goldman Sachs
Truist Securities
SVB Leerink

Ratings for Arcus Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RCUS Stock
  4. Consensus Arcus Biosciences, Inc.